0570 (0570) Fair Value & Analysis

Healthcare · Market cap HK$6.8B

0 0570 0570 · HK

PriceHK$1.35

Fair ValueHK$3.16

Upside+134.1%

Quality52/100

Evidence: Medium Range HK$2.45 – HK$3.88

Fair value as of: Jul 2, 2026

From 11 valuation models · updated today

Share price −13.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.34 – HK$2.59 · fair‑value band HK$2.45 – HK$3.88 · the HK$1.35 price screens below the HK$3.16 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0570 (0570) currently trades at HK$1.35, while our model-based Fair Value estimate is HK$3.16 — implying the stock looks roughly 134.1% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

Over the trailing twelve months, 0570 generated revenue of HK$14.7B at a net margin of -2.3%. Revenue declined 10.4% year over year. It earns a return on equity of -2.0%. The balance sheet holds a net cash position of HK$1.6B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$14.7B

Revenue growth (YoY) -10.4%

Net margin -2.3%

Return on equity -2.0%

Free cash flow HK$2.0B FY2025

Operating margin 3.6%

More key figures

EPS (TTM) HK$-0.0200

EPS growth (YoY) -63.5%

Net cash HK$1.6B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0570 reported revenue of HK$14.7B in FY2025 versus HK$19.1B in FY2021, a compound −6.2%/yr. Reported net income was −HK$342M in FY2025.

Revenue −6.2%/yr

FY21 HK$19.1B

FY22 HK$14.3B

FY23 HK$18.1B

FY24 HK$16.5B

FY25 HK$14.7B

Net income

FY21 HK$1.9B

FY22 HK$764M

FY23 HK$1.3B

FY24 HK$54.1M

FY25 −HK$342M

Is 0570 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥30.99	-37%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$24.45	R$6.33	-74%
Hansoh Pharmaceutical Group 3692	HK$29.32	HK$23.94	-18%
Divi's Laboratories Limited DIVISLAB	₹6,623	₹1,461	-78%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0570 (0570) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$3.16 versus a price of HK$1.35 — about +134% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 0570?

Our model-based fair value for 0570 is HK$3.16 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.35.

What is the quality score of 0570?

0570 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0570 (0570)?

0570 reported trailing-twelve-month revenue of about HK$14.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 0570?

The net profit margin of 0570 is about -2.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.